The Trump administration’s revived rule to end rebates that drugmakers give to middlemen in Medicare is awaiting approval from the Office of Management and Budget and a final rule could be imminent, according to a person familiar with the matter.

The administration has said the rule would drive down the prices consumers pay for prescription drugs. An earlier version of the rule, a signature part of President Trump’s plan to lower drug prices, was withdrawn in 2019 because some White House advisers raised concerns that it could…

This post first appeared on wsj.com

You May Also Like

Norman Jewison, acclaimed director of ‘In the Heat of the Night’ and ‘Moonstruck,’ dies at 97

NEW YORK — Norman Jewison, the acclaimed and versatile Canadian-born director whose Hollywood…

Biden warns Putin against Ukraine invasion as Russia increases troops along border

WASHINGTON — President Joe Biden on Friday pledged to make it “very,…

TikTok Made Them Famous. Figuring Out What’s Next Is Tough.

Before Charli D’Amelio became the most popular creator on TikTok — she…

The Most Interesting Success and Failure of 2022

What was the most interesting success or failure of 2022?  That was…